CorMedix is a newly profitable biotech with elite margins, 156% revenue growth and a 69.9% gap to the analyst target, but revenue depends on three customers, earnings are expected to fall about 83% from a peak, and short interest is 20%.
Thesis pillars
- Elite Profitability And Returns→Stable
- Customer Concentration And Earnings Peak↓Deteriorating
- Analyst Target Upside↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 5, 2026
CorMedix Inc. (CRMD) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $7.67. Critical SEC filing — blocks BUY_NOW at $8.20. Engine's entry $7.67 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: top three customers (79.0%); Earnings expected to decline ~83% (cyclical peak).
CorMedix is a biopharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter lock solution in the U.S. for reducing catheter-related bloodstream infections in hemodialysis patients. The August 2025 acquisition of Melinta Therapeutics added... Read more
Wait for pullback to $7.67. Critical SEC filing — blocks BUY_NOW at $8.20. Engine's entry $7.67 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: top three customers (79.0%); Earnings expected to decline ~83% (cyclical peak). Chart setup: No clear chart pattern; technical signals are mixed. Quality-value play. Wait for momentum improvement. Score 7.2/10, high confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Fails on SEC filing concern. Suitability: speculative.
About CorMedix Inc.
About CorMedix Inc.
CorMedix markets DefenCath, the only FDA-approved antimicrobial catheter lock solution in the U.S., alongside six additional infectious-disease and cardiovascular brands acquired with Melinta Therapeutics in August 2025 — REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. The company reported net income of approximately $163.1 million for 2025, a reversal from a $17.9 million net loss in 2024, with DefenCath the largest contributor to net sales.
DefenCath launched commercially in April 2024 for inpatient hemodialysis and expanded to outpatient dialysis clinics that July, reducing catheter-related bloodstream infections in patients on chronic hemodialysis through a central venous catheter. CorMedix sells DefenCath directly to hospitals and outpatient dialysis center operators and depends on Medicare's Transitional Drug Add-on Payment and New Technology Add-on Payment mechanisms for reimbursement, both of which are scheduled to step down through 2026 and 2027. The Melinta portfolio extends the commercial platform into hospital and clinic anti-infective channels — REZZAYO for candidemia, MINOCIN IV and VABOMERE for resistant gram-negative infections — while REZZAYO's underlying NDA remains held by licensor Mundipharma until a scheduled 2028 transfer. Sales to the top three customers accounted for 79% of total revenue in 2025.
Show full overview
Reimbursement transition risk stands out beyond the headline customer concentration: DefenCath's Transitional Drug Add-on Payment expires July 1, 2026, and CMS's post-TDAPA methodology is expected to cut net pricing for the back half of 2026 before a higher add-on adjustment potentially takes effect January 1, 2027. On June 25, 2026, CorMedix dismissed CBIZ CPAs as its independent registered public accounting firm, a disclosure event distinct from the reimbursement cycle but one that could weigh on near-term financial-reporting continuity alongside the pricing transition.
See also: Healthcare · Biotechnology
From CorMedix Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — CorMedix Inc.
Latest news
- NEWS CorMedix Therapeutics Q2 Results: Earnings and update set for August 13 - scanx.trade — scanx.trade neutral
- NEWS CorMedix Inc (CRMD) Valuation: PE, PB & Fair Value Analysis - TradingKey — TradingKey neutral
- NEWS CorMedix (CRMD) Q2 2026 Earnings Call Transcript - AOL.com — AOL.com neutral
- NEWS CRMD|CorMedix Inc|Price:8.390|Chg%:-0.170 - TradingKey — TradingKey neutral
- NEWS CorMedix (NASDAQ:CRMD) Shares Gap Up - Still a Buy? - MarketBeat — MarketBeat positive
Generated 2026-10-29T12:43:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop three customers79%10-K Item 1A: 'Sales to our top three customers accounted for 79% of our total revenue for the year ended December 31, 2025'
- MEDIUMProductDefenCath10-K Item 1A: 'We are highly dependent on the continued successful commercialization of our lead product, DefenCath.'
- MEDIUMcounterpartyMundipharma10-K Item 1: 'our licensor Napp Pharmaceutical Group Limited, a member of Mundipharma independent associated companies (“Mundipharma”), currently holds the product NDA and intellectual property rights'
Material Events(8-K, last 90d)
- 2026-07-01Item 4.01HIGHOn June 25, 2026, CorMedix's Audit Committee dismissed CBIZ CPAs as its independent registered public accounting firm; no disagreements over accounting principles or financial disclosure were reported, though one reportable event is referenced without detail in the filing excerpt.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $7.67. Critical SEC filing — blocks BUY_NOW at $8.20. Engine's entry $7.67 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: top three customers (79.0%); Earnings expected to decline ~83% (cyclical peak). Chart setup: No clear chart pattern; technical signals are mixed. Quality-value play. Wait for momentum improvement. Target $13.34 (+62.7%), stop $7.13 (−15.0%), A.R:R 4.5:1. Score 7.2/10, high confidence.
Take-profit target: $13.34 (+62.7% upside). Target $13.34 (+62.7%), stop $7.13 (−15.0%), A.R:R 4.5:1. Stop-loss: $7.13.
Concentration risk — Customer: top three customers (79.0%); Earnings expected to decline ~83% (cyclical peak).
CorMedix Inc. trades at a P/E of 4.0 (forward 23.4). TrendMatrix value score: 8.7/10. Verdict: Buy (Wait for Entry).
12 analysts cover CRMD with a consensus score of 4.3/5. Average price target: $15.
What does CorMedix Inc. do?CorMedix is a biopharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter...
CorMedix is a biopharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter lock solution in the U.S. for reducing catheter-related bloodstream infections in hemodialysis patients. The August 2025 acquisition of Melinta Therapeutics added six marketed hospital and clinic infectious-disease products — REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, and BAXDELA — plus the cardiovascular product TOPROL-XL, and the company reported net income of approximately $163.1 million for 2025 versus a $17.9 million net loss in 2024.